Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
- M. Brunet, T. van Gelder, S. Bergan
- Medicine, BiologyTherapeutic Drug Monitoring
- 2019
It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
- I. Lunde, S. Bremer, H. Christensen
- Medicine, BiologyEuropean Journal of Clinical Pharmacology
- 22 March 2014
The results support the use of pre-transplant CYP3A5 genotyping to improve initial dosing of Tac, and suggest that Tac dosing may be further individualized by additional POR and PPARA genotypes.
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
- S. Bergan, M. Brunet, L. Langman
- MedicineTherapeutic Drug Monitoring
- 1 April 2021
ABSTRACT
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized…
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
- P. Falck, N. Vethe, H. Holdaas
- Medicine, ChemistryNephrology, Dialysis and Transplantation
- 15 October 2007
Cinacalcet treatment showed a moderate effect on the Tac, but not CsA or mycophenolate, pharmacokinetics after 1-week concomitant treatment, and this interaction appears to have minor clinical relevance.
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
- E. Molden, P. W. Johansen, G. Lehne
- Biology, MedicineClinical pharmacology and therapy
- 1 September 2002
The aim of this study was to compare the pharmacokinetics of diltiazem and its major metabolites in healthy human volunteers representing different CYP2D6 genotypes.
Calcineurin Inhibitor‐Free Immunosuppression in Renal Allograft Recipients with Thrombotic Microangiopathy/Hemolytic Uremic Syndrome
- O. Øyen, E. H. Strøm, I. Brekke
- Medicine, BiologyAmerican Journal of Transplantation
- 1 February 2006
Thrombotic microangiopathy and hemolytic uremic syndrome represent serious threats to kidney allograft recipients and need to be addressed urgently.
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts.
- S. Bergan, O. Bentdal, G. Sødal, A. Brun, H. Rugstad, O. Stokke
- MedicineTherapeutic Drug Monitoring
- 1 October 1997
It is found that 6-TGN concentrations are very high in neutrophils, whereas me-MPs are undetectable, many explain the specific neutropenic adverse effect of AZA.
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
- E. Egeland, Ida Robertsen, A. Åsberg
- MedicineTransplantation
- 1 August 2017
High estimated clearance is significantly associated with increased risk of BPAR the first 90 days posttransplantation and may predict an increasedrisk of rejection in the early phase after renal transplantation.
Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients
- R. Mandla, P. Line, K. Midtvedt, S. Bergan
- BiologyTherapeutic Drug Monitoring
- 1 June 2003
A fully automated method for the determination of free concentrations by dialysis across a membrane followed by concentration of the dialysate on a trace enrichment column and liquid chromatography has been successfully applied and may provide important data to support the identification of principles and target ranges for the monitoring of mycophenolic acid in the immunosuppressive therapy of organ transplant recipients.
Importance of hematocrit for a tacrolimus target concentration strategy
- E. Størset, N. Holford, K. Midtvedt, S. Bremer, S. Bergan, A. Åsberg
- Medicine, BiologyEuropean Journal of Clinical Pharmacology
- 27 September 2013
Fat-free mass, CYP3A5 genotype, sex, age and time after transplant influence the tacrolimus individual dose requirement, and hematocrit is a key factor in the interpretation of tacolimus whole blood concentrations.
...
...